associated with fasting GLP-1 levels (p = 0.98) after adjustment for age, sex, fat-free mass (FFM), and fat mass (FM). Similarly, no association was observed between RQ and GLP-1 levels (p = 0.95), after adjustment for age, sex, and body fat. Conclusion In adults subjects with increased adiposity fasting, GLP-1 levels do not seem to play a role in the regulation of energy metabolism and in fuel selection.
Introduction
to prolonged satiety [1, 2] . Given the multifaceted effects of GLP-1, its potential involvement in energy balance and energy metabolism, other than the regulation of food intake, has been postulated. However, evidence is conflicting regarding the effects of GLP-1 on energy expenditure [1] .
Among the earlier studies, an increase in oxygen consumption, as indicator of a thermogenic effect, was observed after intracerebroventricular administration of GLP-1 in lean rats, but the effect was blunted in obese animals [7] . Central administration of a GLP-1 receptor agonist in animals activated the central autonomic system, stimulating the sympathetic pathways [8, 9] . Since thermogenesis is under control of the sympathetic nervous system (SNS), through its neurotransmitter norepinephrine [10, 11] , it has been suggested that the effects of GLP-1 on the SNS may interfere with the regulation of energy metabolism, but this interaction has been poorly investigated in humans.
Therefore, the aim of our study was to explore the relationships between fasting plasma concentrations of GLP-1 and resting energy expenditure, fuel selection, and 24-h urinary norepinephrine levels in subjects with overweight and obesity.
Materials and methods
Study participants were recruited among subjects referring to the outpatient Dietetic and Metabolic Unit, University of Pavia, Italy [12] . Inclusion criteria were age ≥ 25 and ≤ 45 years, body mass index (BMI) ≥ 25 and ≤ 35 kg/ m 2 , and weight stable within the last 3 months. Subjects with history of diabetes, chronic renal disease, viral or autoimmune hepatic disease, uncompensated cardiovascular diseases, uncontrolled hypertension, eating disorders, untreated thyroid disorders, diagnosed or suspected psychiatric disorders, and cancer within the last 5 years were excluded from the study. Subjects were also excluded if they had any overt or subclinical thyroid dysfunctions, had undergone bariatric surgery procedures, were participating in a weight loss program or taking medications for weight loss, were currently exercising, were pregnant or lactating, or had entered menopause, and had history of smoking and alcohol intake.
All subjects underwent physical examination, body composition assessment, and routine laboratory testing. The study protocol was approved by the local Ethics Committee, University of Pavia, Italy. All participants provided written informed consent.
Body composition
Fat-free mass (FFM) and fat mass (FM) were assessed by dual-energy X-ray absorptiometry (DXA) (Lunar Prodigy, GE Medical Systems, Waukesha, WI, USA).
Resting energy expenditure (REE)
Respiratory gas exchanges (VO 2 and VCO 2 ) were measured by indirect calorimetry after an overnight fast using a ventilated hood system (Deltatrac Monitor II MBM-200, Datex Engstrom Division, Instruments Corp. Helsinki, Finland), following standardized procedures and recommendations [13] . 24-h urinary nitrogen excretion was measured, and REE was estimated using the Weir formula [14] , and expressed as kcal/24 h. Respiratory quotient (RQ) was also calculated, and used as an indicator of fuel selection.
Laboratory data
After a 12-h fast, blood samples were drawn from the antecubital vein and were collected into Vacutainer EDTAplasma tubes, and an appropriate amount (10 µl per ml of blood) of dipeptidyl peptidase-4 inhibitor (DRG Diagnostics, Marburg, Germany) was immediately added (within 30 s). Plasma levels of bioactive GLP-1 were measured using an enzyme-linked immunosorbent assay kit (Epitope Diagnostics, Inc., San Diego, CA). This test has an intraassay CV of 3.9%, interassay CV of 4.7%; limits of detection of 0.05 pmol/l. A 24-h urine sample was collected for the measurement of norepinephrine excretion. Serum levels of free fatty acids (FFA) were determined by a quantitative colorimetric assay (BioAssay Systems, Hayward, CA). Plasma glucose and insulin levels were measured using commercial kits. Homeostasis model assessments of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) were calculated as previously described [15] . Serum adiponectin and leptin levels were measured using ELISA kits (both R&D Systems, Inc., Minneapolis, MN, USA).
Statistics
Distributions of continuous variables were examined for skewness and kurtosis, and were logarithmically transformed when appropriate to adjust distributional patterns. Log-transformed variables are presented as untransformed values for ease of reading. Differences between men and women were examined using Student's t test, and ANCOVA was used for adjustments for the variables specified in the text and tables. Pearson's correlation was used to examine the relationship between variables. Multiple linear regression analyses were used to examine association between GLP-1 levels and the variables included in the different models. Statistical significance was set at p < 0.05. Data analysis was performed using Stata 11.2.
Results
Thirty-seven participants were enrolled [10 men and 27 women; age (mean ± standard error): 43 ± 2 years; BMI 30.6 ± 0.5 kg/m 2 ]. Though the range of BMI included both overweight and obesity categories, all study participants were overtly obese according to body fat percentage when considering 25% in men and 35% in women as cut points for body fat [16] . The clinical and biochemical characteristics of participants according to sex are described in Table 1 . There were no significant differences in BMI and age between men and women, though men tended to be older than women. Body fat percentage and absolute fat mass (47.4 ± 0.8 vs. 32.4 ± 1.9%; p < 0.001 and 37.4 ± 1.3 vs. 29.1 ± 2.6; p = 0.009, respectively) were significantly higher in women than men, while FFM was significantly lower (41.2 ± 0.7 vs. 60.0 ± 2.5 kg; p < 0.001), after adjustment for age. Fasting glucose (97.3 ± 2.9 vs. 88.3 ± 1.3 mg/dl; p = 0.04), insulin (12.8 ± 1.7 vs. 9.1 ± 0.8 µU/ml; p = 0.02), and HOMA-IR levels (3.13 ± 0.52 vs. 1.94 ± 0.19; p = 0.01) were significantly higher in men than women after adjustment for age and body fat. Plasma adiponectin concentrations were significantly higher in women than men (101.3 ± 60.2 vs. 54.6 ± 9.1 µg/ml; p = 0.02) after adjustment for age and body fat. No significant differences between sex were observed in HOMA-β, free fatty acids, leptin, fasting GLP-1 levels, and urinary norepinephrine concentrations. RQ and REE were not significantly different between men and women, after adjustment for age and body fat, and after adjustment for age, fat-free mass, and fat mass, respectively. When study participants were divided into two groups: low GLP-1 group vs. high GLP-1 group, according to the median values of endogenous GLP-1, no differences in REE were observed between groups after adjustment for age, sex, FFM, and FM (p > 0.05, Fig. 1) . Similarly, RQ in the low GLP-1 group was not significantly different from the high GLP-1 group after adjustment for age, sex, and body fat (p > 0.05, Fig. 2 ).
As shown in Table 2 , no significant relationship emerged between fasting GLP-1 levels and body composition parameters. In addition, GLP-1 concentrations were not correlated with HOMA-IR, HOMA-β, FFA, leptin, adiponectin, or urinary norepinephrine, after controlling for age, sex, and fat mass. Results from the multiple regression analysis are reported in Tables 3 and 4 . REE was not significantly associated with fasting GLP-1 levels after adjustment for age, sex, FFM, and FM (Table 3 , Model 1), with FFM and FM being the only variables positively significantly associated with REE (p = 0.01 and p = 0.002, respectively). This relationship remained not significant after adjustment for urinary 
Discussion
In the present study, no association emerged between fasting plasma GLP-1 and resting energy expenditure, as well as between fasting plasma GLP-1 and respiratory quotient in non-diabetic, obese subjects. Thus, our results confirm the previous findings from human studies. In accordance with their previous results in normal-weight men [17] , Flint et al. showed that the peripheral infusion of GLP-1 in physiological concentrations in healthy obese individuals resulted in a decreased diet-induced thermogenesis and substrate oxidation when compared to saline infusion [18] . These findings were explained by the delayed nutrient absorption due to the slowing of gastric emptying by GLP-1. In a study involving non-diabetic overweight and obese men, Tan et al. found that resting energy expenditure, respiratory quotient, and substrate oxidation rates did not significantly change during GLP-1 infusion alone [19] . Likewise, Bagger et al. reported that the infusion of GLP-1 did not produce any significant effect on resting energy expenditure as measured by oxygen uptake during a liquid meal test [20] . In addition, in a long-term study in non-diabetic subjects with obesity, the administration of exenatide, a GLP-1 analog, over a 12-week period did not change weight-adjusted total energy expenditure-assessed by doubly labeled water, resting metabolic rate, and thermic effect of meals via indirect calorimetry [21] . More recently, in a randomized, placebo-controlled crossover trial in non-diabetic adults with obesity, van Can et al. demonstrated that treatment with liraglutide, another GLP-1 analog, for 5 weeks reduced 24-h energy expenditure and 24-h RQ (as assessed during a 24-h stay in an open-circuit respiratory chamber) indicating a preferential fat oxidation, but the decline in energy expenditure was attributed to the parallel treatment-related decrease in body weight [22] . Conversely, our findings are in disagreement with the results of Pannacciulli et al. [23] and Shalev et al. [24] . In a study involving glucose tolerant adult subjects with a wide range of BMIs (18.5-50 kg/m 2 ), Pannacciulli et al. [23] found a positive association between fasting GLP-1 levels and REE, and a negative association between GLP-1 concentrations and RQ. In a study consisting of healthy normal-weight men, Shalev et al. found that pharmacological GLP-1 infusion (in supraphysiological doses) elicited, during hyperglycemic clamping, a significant rise in energy expenditure as well as in respiratory quotient compared to saline infusion. However, following the administration of somatostatin, counteracting the GLP-1-induced insulin secretion, no significant differences in energy expenditure or respiratory quotient were observed between the GLP-1 and the placebo protocol. These findings suggest that the thermic effect was mediated by GLP-1-induced hyperinsulinemia rather than by GLP-1 [24] . Indeed, in the fed state, insulin promotes cellular use of nutrients with a subsequent effect on diet-induced thermogenesis. Hence, the suppression of insulin secretion by somatostatin may account for the lack of any effect of GLP-1 per se on oxygen consumption. On the other hand, in the fasting state, fat oxidation is predominant in the presence of insulin sensitivity, and this may explain the significant negative association between fasting GLP-1 levels and RQ (with a lower RQ indicating a preferential fat utilization) observed by Pannacciulli et al. [23] in their study population consisting of participants with normal glucose homeostasis. On the contrary, in 34% of our participants, HOMA-IR was ≥ 2.5 [25] , indicating the presence of insulin resistance (data not shown). In conclusion, differences among the studies, mainly in methodology, may be responsible for the discrepant results. Such differences include the timing of the study with respect to food consumption (the fasting state or the post-absorptive state); the route of administration of GLP-1 (peripheral or central infusion) vs. the evaluation of endogenous GLP-1 levels; the use of native GLP-1 versus GLP-1 analogs; and, importantly, the population studied (normal weight versus obese; subjects with altered versus preserved insulin sensitivity).
In the present study, we also observed that fasting GLP-1 concentrations were not associated with urinary norepinephrine levels. This finding is in line with the data reported in healthy individuals receiving a pharmacological dose of exogenous GLP-1 or placebo during hyperinsulinemic, stepped hypoglycemic clamp experiments [26] . No significant effect was attributed to GLP-1 for the changes in plasma norepinephrine levels. These observations are in the opposite direction when compared to animal data, showing the activation of the catecholaminergic neurons in the rat brain by a GLP-1 receptor agonist [8, 9] . The parallel obesity-related derangements in GLP-1 and catecholamine levels can both affect and blunt their contribution to energy expenditure, and this may be the reason for the disagreement between our findings and evidence from other human or animal studies [9, 23, 26] . In fact, several animal and human studies described a defective SNS activity potentially related to decreased stimulation of energy expenditure in obesity [27, 28] , and an association has been reported between decreased SNS tone and weight gain and obesity [29] . Likewise, the increase of GLP-1 following weight loss suggests that obesity drives changes in GLP-1 levels and activity [1, 30] .
In summary, in adults, subjects with increased adiposity fasting GLP-1 levels do not play a role in the regulation of energy metabolism and in fuel selection. The present findings may be affected by the presence of excess fat as well as by different degrees of insulin resistance. Further studies should evaluate discrepancies related to the detrimental effects of obesity on insulin sensitivity, GLP-1 levels, SNS functioning, and their interrelationship. Moreover, our results need to be verified in the postprandial state, to clarify the role of GLP-1 in body weight regulation independent of its well-known effects on satiety and feeding behavior. A better understanding of the role played by GLP-1 in the regulation of energy metabolism and its interactions with other mediators of fuel homeostasis [31] could expand therapeutic strategies for obesity management.
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